Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/56985
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Casson, R. | - |
dc.contributor.author | Liu, L. | - |
dc.contributor.author | Graham, S. | - |
dc.contributor.author | Morgan, W. | - |
dc.contributor.author | Grigg, J. | - |
dc.contributor.author | Galanopoulos, A. | - |
dc.contributor.author | Crawford, A. | - |
dc.contributor.author | House, P. | - |
dc.date.issued | 2009 | - |
dc.identifier.citation | Journal of Glaucoma, 2009; 18(8):582-588 | - |
dc.identifier.issn | 1057-0829 | - |
dc.identifier.issn | 1536-481X | - |
dc.identifier.uri | http://hdl.handle.net/2440/56985 | - |
dc.description | © 2009 Lippincott Williams & Wilkins, Inc. | - |
dc.description.abstract | <h4>Purpose</h4>To assess the efficacy and safety of switching patients from bilateral latanoprost to bimatoprost in 1 eye while maintaining latanoprost in the fellow eye.<h4>Patients and methods</h4>This prospective, open-label, multicenter, uniocular (within-eye control) study was conducted from March 2005 to February 2007; 105 patients with glaucoma or ocular hypertension were enrolled. At baseline, patients using bilateral latanoprost were switched to bimatoprost treatment in 1 eye (study eye) and continued latanoprost treatment in the fellow eye (control eye). At 12 weeks, patients were offered bilateral bimatoprost for 12 additional weeks.<h4>Results</h4>At week 12, the mean difference in intraocular pressure (IOP) from baseline was -3.0 mm Hg in study eyes and -1.6 mm Hg in control eyes, which equates to a further -1.4 mm Hg (95% confidence limits: -1.9, -0.9) reduction in IOP in study eyes compared with control eyes (P<0.0001). Overall, 27% (28/104) more study eyes had > or = -2.5 mm Hg reduction in IOP than control eyes (P<0001). At week 24, the mean difference in IOP from baseline was -2.8 mm Hg for study eyes and for control eyes that had switched to bimatoprost. Conjunctival hyperemia occurred more frequently and was more severe in bimatoprost-treated eyes at week 12 than at baseline (P<0.001). No patients withdrew from treatment because of conjunctival hyperemia.<h4>Conclusions</h4>Clinically, these data suggest that switching patients from latanoprost to bimatoprost may result in further improvement in IOP control. | - |
dc.description.statementofresponsibility | Robert J. Casson, Lance Liu, Stuart L. Graham, William H. Morgan, John R. Grigg, Anna Galanopoulos, Andrew Crawford, Philip H. House | - |
dc.language.iso | en | - |
dc.publisher | Lippincott Williams & Wilkins | - |
dc.source.uri | http://journals.lww.com/glaucomajournal/Abstract/2009/10000/Efficacy_and_Safety_of_Bimatoprost_as_Replacement.4.aspx | - |
dc.subject | open angle glaucoma | - |
dc.subject | ocular hypertension | - |
dc.subject | bimatoprost | - |
dc.subject | latanoprost | - |
dc.subject | prostaglandin analogs | - |
dc.title | Efficacy and safety of Bimatoprost as replacement for Latanoprost in patients with glaucoma or ocular hypertension: A uniocular switch study | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1097/IJG.0b013e318199722b | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Casson, R. [0000-0003-2822-4076] | - |
Appears in Collections: | Aurora harvest Opthalmology & Visual Sciences publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.